Gerhard Mayr - UCB SA Non-Executive Chairman of the Board
| UCB Stock | EUR 119.35 0.10 0.08% |
Chairman
Mr. Gerhard N. Mayr has served as NonExecutive Chairman of the Board of U C B S.A. since May 2012. He served as NonExecutive Independent Director of the Company between June 14, 2005 and May 2012. He received a Master degree in Chemical Engineering from the Swiss Federal Institute of Technology in 1969, and a MBA degree from Stanford University in 1972. In March 2004, he retired as Executive Vice President of pharmaceutical operations at Eli Lilly Company after 32 years of service since 2012.
| Age | 68 |
| Tenure | 12 years |
| Phone | 32 2 559 99 99 |
| Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Albrecht Graeve | NV Bekaert SA | 62 | |
| Jurgen Tinggren | NV Bekaert SA | N/A | |
| Charles Beauduin | Barco NV | 64 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 |
UCB SA Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
| Detlef Thielgen, CFO and Executive VP | ||
| Kay Davies, Independent Director | ||
| Dirk Teuwen, VP Corporate Societal Responsibility | ||
| Anna Richo, Executive VP and General Counsel | ||
| Viviane Monges, Independent Non-Executive Director | ||
| Gerhard Mayr, Non-Executive Chairman of the Board | ||
| Cyril Janssen, Director | ||
| Caroline Vancoillie, Chief Functions | ||
| Cedric Rijckevorsel, Director | ||
| JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
| Arnoud Calesberg, Non-Executive Director | ||
| Mark McDade, COO and Executive VP | ||
| Xavier Michel, Vice President and Secretary General | ||
| Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
| Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
| Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
| Norman Ornstein, Non-Executive Independent Director | ||
| Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
| JeanPierre Kinet, Non-Executive Independent Director | ||
| Antje Witte, VP of Investor Relations | ||
| Alice Dautry, Independent Director | ||
| Sandrine CFA, Ex CFO | ||
| Harriet Edelman, Non-Executive Independent Director | ||
| Ulf Wiinberg, Independent Director | ||
| William Silbey, Exec Counsel | ||
| Thomas McKillop, Non-Executive Independent Director | ||
| Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
| France Nivelle, VP Global Communication | ||
| Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
| Pierre Gurdjian, Independent Director | ||
| Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
| Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
| Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
| Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
| CharlesAntoine Janssen, Non-Executive Director | ||
| Pr LowFriedrich, Chief VP | ||
| Kirsten LundJurgensen, Ex Solutions | ||
| Albrecht Graeve, Non-Executive Independent Director | ||
| JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
| Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 15.81 B | |||
| Shares Outstanding | 189.96 M | |||
| Shares Owned By Insiders | 38.03 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Earning | 17.19 X | |||
| Price To Book | 1.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the UCB SA information on this page should be used as a complementary analysis to other UCB SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for UCB Stock analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |